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The Authors Reply: We are aware of the new 
diabetes criteria mentioned by Barajas-Gamboa 
and Diaz-Perez. However, glycated hemoglobin 
level was not typically included in the diagnosis 
of diabetes when the SOS study started in 1987, 
and glucose-tolerance testing at more than 500 
study sites was not logistically achievable. We 
carefully specified the criteria used for diabetes 
diagnosis in our article, and the fact that they are 
not in agreement with the latest definitions was 
also pointed out as a limitation. We have no 
reason to believe that slightly different criteria 
would have changed our conclusion that bariatric 
surgery prevents diabetes.
In response to Zaccardi et al.: we would point 
out that there are no real conflicts between their 
statements and our findings. In the SOS study 
population (BMI ≥34), we have found no interac-
tions between BMI and treatment (or between 
other anthropometric variables and treatment) 
with respect to the incidence of diabetes,1 car-
diovascular events,2 or cancer3 or with respect to 
overall mortality,4 whereas glucose and insulin 
levels were predictors of treatment effect for sev-
eral of these end points. We agree that reduced 
insulin resistance may be one of the mechanisms 
behind the effects of bariatric surgery, and for 
cardiovascular events, the baseline insulin level 
was the only predictor (among 20 variables 
tested) of the surgical treatment effect.2 Sub-
group–treatment interactions with respect to 
hard end points are, to the best of our knowl-
edge, not available in other studies of bariatric 
surgery.
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Antibiotic Prevention of Acute Exacerbations of COPD
To the Editor: Wenzel and colleagues (July 26 
issue)1 recommend long-term azithromycin for a 
55-year-old man with recurrent exacerbations of 
chronic obstructive pulmonary disease (COPD), 
a forced expiratory volume in 1 second (FEV1) of 
50% of the predicted value, dyspnea, cough, and 
sputum production. However, before azithromy-
cin, we think this patient should be treated with 
other pharmacologic agents to manage his COPD 
and prevent exacerbations.
Tiotropium is a long-acting anticholinergic 
bronchodilator that improves the FEV1 and health-
related quality of life. Tiotropium reduces the 
frequency of exacerbations and related hospital-
izations. More important, tiotropium is effective 
even when patients are receiving inhaled gluco-
corticoids and long-acting beta-agonists.2
This patient’s history of cough and sputum 
production suggests chronic bronchitis. The 
phosphodiesterase-4 inhibitor roflumilast reduc-
es moderate-to-severe exacerbations in patients 
with chronic bronchitis, severe-to-very-severe 
COPD, and a history of exacerbations. Favorable 
effects are also seen when roflumilast is added 
to long-acting bronchodilators.3
In our view, before recommending azithro-
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mycin, this patient should be treated with tiotro-
pium. Roflumilast should be added if he contin-
ues to have exacerbations. Azithromycin should 
be considered only if the exacerbations are not 
adequately controlled despite the addition of 
tiotropium and roflumilast.
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To the Editor: Wenzel et al. describe adverse 
effects that may occur with yearlong use of azith-
romycin to prevent exacerbations of COPD. These 
adverse effects include hearing loss, a prolonged 
QTc interval associated with an increased risk of 
torsades de pointes, and drug–drug interactions. 
The authors also express concern about the de-
velopment of bacterial resistance to azithromy-
cin. To decrease the potential for harm, the 
 authors suggest audiography and electrocardiog-
raphy at the initial screening and every 3 months. 
The potential benefit is to reduce the frequency 
of COPD exacerbations from 1.83 to 1.48 per 
patient-year, and yearlong azithromycin treatment 
may result in fewer COPD-related hospitaliza-
tions.1
Another approach is to give the patient azith-
romycin and instructions to begin treatment for 
5 days if a worsening cough or change in sputum 
color or amount occurs. The therapeutic benefit 
of this approach is suggested by a recent study 
that showed that pulsed 5-day treatment with 
moxifloxacin at a dose of 400 mg once a day 
every 8 weeks for 48 weeks was most effective in 
the subgroup of 323 patients with purulent spu-
tum at baseline.2 Less frequent antibiotic use will 
decrease adverse effects, the need for monitor-
ing, and expense.
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To the Editor: Wenzel et al. endorse the use of 
long-term prophylactic antibiotic therapy in cer-
tain patients with COPD. They support their rec-
ommendation with data from a trial by Albert et 
al.1 showing the “frequency of exacerbations was 
1.48 per year in the azithromycin group versus 
1.83 in the placebo group.” However, although 
there was a modest improvement in the number 
of exacerbations, there was no significant differ-
ence in overall mortality between the groups. 
This finding raises an important question: Is it 
reasonable to endorse long-term prophylactic an-
tibiotic therapy when there is no mortality bene-
fit? It is clear that long-term use will hasten anti-
biotic resistance. The patient is, in effect, acting 
as culture medium to grow azithromycin-resis-
tant organisms. Although the patient receives a 
modest benefit, the cost is going to be inflicted 
on society at large. In fact, the development of 
routine antibiotic resistance may even lead to an 
increased mortality in the population as a whole. 
Antibiotics are a communal resource, and the 
use of these agents on a long-term basis for rea-
sons other than the prevention of death shows 
the selfish individualism of modern medicine 
and should not be taken lightly.
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To the Editor: Wenzel et al. review the use of 
macrolide therapy for the prevention of COPD ex-
acerbations. However, we have some concerns 
about the extrapolation of their conclusions 
worldwide. Different epidemiologic characteris-
tics, rates of antibiotic resistance, and mecha-
nisms of resistance among respiratory pathogens 
could be encountered in different countries.
The prevalence of macrolide-resistant Strepto-
coccus pneumoniae, a major type of bacteria iso-
lated in patients admitted for COPD exacerba-
tion, is close to 96% in some Asian countries.1 
Moreover, there are two common mechanisms 
of macrolide resistance in S. pneumoniae. The first 
mechanism involves the site where macrolides 
bind to the ribosome; this mechanism accounts 
for more than 90% of the macrolide-resistant 
isolate strains in Europe and confers high resis-
tance (minimum inhibitory concentration, ≥64 
μg per milliliter).2 The second mechanism is 
caused by an efflux pump; this mechanism ac-
counts for more than 65% of the macrolide-re-
sistant isolate strains in the United States3 and 
confers a low level of macrolide resistance 
(minimum inhibitory concentration, ≥4 μg per 
milliliter). The study conducted by Albert et al.4 
was performed in the United States.
Before the use of azithromycin can be recom-
mended worldwide, further studies should be 
performed in different geographic areas.
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To the Editor: In their review of long-term azith-
romycin use for prevention of COPD exacerba-
tions, Wenzel and coauthors acknowledge the 
risk of the development of infection with macro-
lide-resistant nontuberculous mycobacteria, and 
they recommend screening for mycobacteria be-
fore the initiation of azithromycin therapy and 
not administering this prophylaxis to patients 
with positive sputum cultures. The relationship 
between macrolides and nontuberculous myco-
bacteria may be more complex than described, 
however. In addition to the specific risk of mac-
rolide resistance,1 retrospective studies involving 
patients with cystic fibrosis suggest that azithro-
mycin may increase the risk of the development 
of infections with nontuberculous mycobacte-
ria,2,3 and widespread use of long-term azithro-
mycin may in part explain the alarming increase 
in the incidence of infections with nontubercu-
lous mycobacteria observed in patients with 
cystic fibrosis. Experimental evidence suggests a 
paradoxical effect of azithromycin on nontuber-
culous mycobacteria, with bactericidal effects 
offset by reduced mycobacterial killing through 
inhibition of macrophage autophagy3 — a more 
complex picture than that depicted in Figure 1 of 
the article by Wenzel et al. As the authors note, 
the long-term adverse effects of macrolide use in 
patients with COPD remain unknown, but clini-
cians should remain alert to the possibility of the 
development of nontuberculous mycobacterial 
disease in patients during prolonged use of azith-
romycin prophylaxis.
Stephen J. Chapman, D.M.
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The Authors Reply: Zaidi and Nawab argue that 
tiotropium or roflumilast could be initiated be-
fore considering azithromycin prophylaxis. Each 
suggestion has merit, but we offer some cau-
tions. A recent meta-analysis revealed that pa-
tients receiving tiotropium had a modest reduc-
tion of 0.3 exacerbations per patient-year.1 
Roflumilast was associated with a reduction in 
the rates of moderate-to-severe exacerbations: 
1.14 per patient-year with roflumilast versus 1.37 
with placebo.2 However, diarrhea (sometimes re-
quiring hospitalization), nausea, and headache 
are common with roflumilast. Dose-limiting 
weight loss and depression may also occur.
Citing a study of pulsed moxifloxacin prophy-
laxis, Siegel argues for the preemptive use of 
azithromycin at the first sign of a possible exac-
erbation. Moxifloxacin was associated with a 
reduction in exacerbations by 19% but was not 
associated with improvement in lung function or 
quality-of-life score.3 Nevertheless, we do not 
think there are sufficient data to endorse the use 
of moxifloxacin or azithromycin preemptively.
Schwarz suggests that since no mortality 
benefit has been demonstrated, society at large 
could lose as a result of widespread antibiotic 
use in individual patients. His is a provocative 
medical and ethical focus on the principle of 
justice. Formal risk–benefit studies involving 
large numbers of patients with COPD would of-
fer insights on morbidity, mortality, and costs of 
antibiotic prophylaxis. We would offer caution, 
however, with regard to a sole focus on mortal-
ity, because patients with COPD exacerbations 
have progressive decreases in lung function and 
quality of life and increases in disability. They 
often live and eventually die with marked air 
hunger.
We agree with Garcia-Vidal et al. that find-
ings in studies of azithromycin in one part of 
the world may not apply equally in all countries. 
Since azithromycin may have important antiin-
flammatory activity, however, it may be prema-
ture to focus on varying mechanisms of antibac-
terial resistance in different regions globally.
Chapman focuses on the emergence of infec-
tions with nontuberculous mycobacteria among 
patients with cystic fibrosis who have received 
prophylactic azithromycin. He warns that a 
similar emergence could happen among patients 
with COPD as well. In the study involving pa-
tients with cystic fibrosis from Israel cited by 
Chapman, although there were differences in a 
univariate analysis relating prior azithromycin 
use to infections with nontuberculous mycobac-
teria, the multivariate analysis showed none — 
the adjusted odds ratio was 1.0.4 In the study 
from the United Kingdom, at a single center a 
correlation over time was noted between the 
number of patients with cystic fibrosis receiving 
long-term azithromycin therapy and the number 
with new nontuberculous mycobacteria cul-
tures.5 Causality cannot yet be ascribed, howev-
er. We appreciate the concern aroused but con-
clude that screening for colonization with 
nontuberculous mycobacteria more than once a 
year is currently unwarranted.
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A Sea-Urchin Spine Chilling Remedy
To the Editor: One of the potential conse-
quences of recreational diving and surfing is in-
jury caused by a sea-urchin spine. Injury can oc-
cur as people enter or exit rocky shorelines and is 
felt immediately as a sharp, localized pain, which 
is exacerbated by the application of pressure. If 
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